Ronapreve for prophylaxis and treatment of covid-19
David B Sidebottom, Dipender Gill
Abstract
On 20 August 2021, Ronapreve received conditional marketing authorisation for the prevention and treatment of covid-19 in the UK. 1 Ronapreve (REGEN-COV in the US) comprises two monoclonal antibodies, casirivimab and imdevimab, that target the SARS-CoV-2 spike protein to reduce the risk and severity of covid-19 in selected patients. 2 -5 Although Ronapreve's approval represents a welcome expansion in the armamentarium against covid-19, it also brings difficult questions about who should be eligible for treatment.
Topics & Concepts
Medical prescriptionContext (archaeology)Focus groupThematic analysisMedicineHealth careFamily medicinePillEnvironmental healthNursingQualitative researchBusinessGeographyEconomic growthMarketingSociologySocial scienceEconomicsArchaeologySARS-CoV-2 and COVID-19 ResearchAntibiotic Use and ResistanceVaccine Coverage and Hesitancy